Background PALB2 has recently been identified as a breast cancer susceptibility gene. PALB2 mutations are rare causes of hereditary breast cancer but may be important in countries such as Finland where a founder mutation is present. We sought to estimate the contribution of PALB2 mutations to the burden of breast cancer in French Canadians from Quebec.

BACKGROUND This study addressed the question of whether limited surgery for primary malignant melanoma with a 2‐cm margin is as good as a 5‐cm margin. An update of a 16‐year follow‐up is provided. METHODS Nine European Centers, over a period of 5 years, prospectively randomized 337 patients with melanoma measuring less than 2.1 mm in thickness to undergo a local excision with either a 2‐cm or a 5‐cm margin. Three hundred twenty‐six patients were eligible for statistical analysis. Excluded from the trial were patients older than 70 years; those with melanomas from the toe, nail, or finger; and those with acral‐lentiginous melanoma. A separate randomization was performed to independently test an adjuvant treatment with a nonspecific immunostimulant, isoprinosine, compared with observation. The median follow‐up time was 192 months (16 years) for the estimation of survival and disease recurrences. RESULTS There were 22 tumor recurrences in the 2‐cm arm and 33 in the 5‐cm arm. The median time to disease recurrence was 43 months and 37.6 months, respectively. The 10‐year disease‐free survival rates were 85% for the group with a 2‐cm margin and 83% for the group with a 5‐cm margin. There was no difference in the 10‐year overall survival rates (87% vs. 86%). Isoprinosine did not demonstrate any activity in this setting. CONCLUSIONS The authors concluded that for melanoma less than 2.1‐mm thick, a margin of excision of 2 cm is sufficient. A larger margin of 5 cm does not appear to have any impact on either the rate or the time to disease recurrence or on survival. Cancer 2003;97:1941–6. © 2003 American Cancer Society. DOI 10.1002/cncr.11272

Treatment according to consensus recommendations is associated with improved survival of women with breast cancer in the community. Promoting the adoption of guidelines for treatment is an effective strategy for disease control.